Enovis (NYSE:ENOV) Trading Down 7.9% on Analyst Downgrade

Enovis Corporation (NYSE:ENOV) shares were down 7.9% on Tuesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The company traded as low as $20.11 and last traded at $20.2730. 87,471 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 1,058,294 shares. The stock had previously closed at $22.02.

ENOV has been the topic of several other reports. William Blair started coverage on Enovis in a research report on Friday, April 17th. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Sunday. Evercore restated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in Enovis by 11.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock valued at $20,086,000 after acquiring an additional 78,497 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. purchased a new stake in shares of Enovis during the fourth quarter valued at approximately $2,929,000. Invenomic Capital Management LP lifted its position in shares of Enovis by 22.7% during the third quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock worth $21,622,000 after purchasing an additional 131,705 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Enovis by 36.5% during the fourth quarter. Impax Asset Management Group plc now owns 424,130 shares of the company’s stock worth $11,299,000 after purchasing an additional 113,500 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Enovis by 14.6% in the fourth quarter. Royce & Associates LP now owns 826,848 shares of the company’s stock valued at $22,027,000 after purchasing an additional 105,608 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -1.01 and a beta of 1.39. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock’s fifty day moving average is $23.28 and its two-hundred day moving average is $23.90.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.